Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Adalimumab/Duloxetine/Ustekinumab

Heart failure with reduced ejection fraction secondary to non-ischaemic dilated cardiomyopathy and loss of response

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Morgenweck E, et al. Heart failure associated with ustekinumab therapy for treatment of Crohn's Disease. Drug and Therapeutics Bulletin 61: 1-3, No. 11, Jun 2023. Available from: URL: https://dx.doi.org/10.1136/dtb.2023.250376rep Morgenweck E, et al. Heart failure associated with ustekinumab therapy for treatment of Crohn's Disease. Drug and Therapeutics Bulletin 61: 1-3, No. 11, Jun 2023. Available from: URL: https://dx.doi.org/10.1136/dtb.2023.250376rep
Metadaten
Titel
Adalimumab/Duloxetine/Ustekinumab
Heart failure with reduced ejection fraction secondary to non-ischaemic dilated cardiomyopathy and loss of response
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52162-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Remternetug

Case report

Imatinib